Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
Hosted on MSN2d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsBiotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
While the spotlight has been on the SEC’s legal battles and XRP’s market movements, savvy investors have been securing their ...
As investors seek high-growth opportunities in the evolving crypto market, projects with strong fundamentals and real-world ...
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
18h
Hosted on MSNPepeto Targets 100x Gains While Wall Street Pepe Hits 10x—Which Meme Coin Will Dominate Binance?Wall Street Pepe Completes Presale, Forecasting 10x Gains Wall Street Pepe ($WEPE) has wrapped up its presale, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results